Astellas Pharma Inc (ALPMY) 14.6600 $ALPMY Tokai Pharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 14.6600 $ALPMY

Tokai Pharma initiates late-stage study of galeterone in prostate cancer
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:54AM CDT

MDVN: 106.81 (-2.19), TKAI: 13.69 (+0.97), QGEN: 25.73 (+1.00)

Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 23, 2:55PM CDT
Vical Incorporated (VICL) announced disappointing top-line data from a phase I/II study on its investigational genital herpes vaccine.
VICL: 0.70 (unch), GILD: 113.74 (+0.38), ACOR: 34.07 (+0.65)

Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 09, 9:00AM CDT
Roche Holding Ag (RHHBY) announced that it has entered into an agreement to develop a companion diagnostic (CDx) test for DalCor Pharmaceuticals' dalcetrapib.
VRX: 232.32 (+8.93), GILD: 113.74 (+0.38)

Astellas Pharma completes enrollment in CMV vaccine trial
Seeking Alpha - at Seeking Alpha - Thu May 21, 8:59AM CDT

VICL: 0.70 (unch)

Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 1:25PM CDT
Astellas Pharma Inc. (ALPMY) announced positive results from a phase IIIb study on Myrbetriq-VESIcare add-on therapy in incontinent overactive bladder patients.
ACT: 298.98 (-2.94), VRX: 232.32 (+8.93)

Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT

MDVN: 106.81 (-2.19), JNJ: 99.53 (+1.13)

Vical Q1 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:24PM CDT
Vical Incorporated (VICL) posted a narrower-than-expected loss of 4 cents per share in the first quarter of 2015 driven by a year-over-year surge in revenues.
VICL: 0.70 (unch), ILMN: 219.45 (+2.28), HSP: 89.15 (+0.02)

Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 08, 2:00PM CDT
Medivation's (MDVN) first quarter results were disappointing with the company missing on both the top and the bottom-lines.
MDVN: 106.81 (-2.19), GILD: 113.74 (+0.38), OSIR: 19.31 (+0.65)

Astellas and Potenza Therapeutics team up in cancer R&D
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:54AM CDT


Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.44 (+2.18), VRX: 232.32 (+8.93)

Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 6.10 (+0.02), PFE: 34.36 (+0.50)

Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), LCI: 59.93 (+2.37)

Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT

MDVN: 106.81 (-2.19)

Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 3:17PM CDT
Vical (VICL) expanded its infectious disease portfolio by acquiring Astellas' (ALPMY) antifungal candidate, ASP2397.
LCI: 59.93 (+2.37), VICL: 0.70 (unch), CBM: 45.61 (+1.91)

Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 2:20PM CDT
Medivation, Inc. (MDVN) and Astellas Pharma jointly announced new data from a randomized, double-blind phase II study (TERRAIN) on Xtandi.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), AZN: 66.45 (+1.90)

Xtandi beats bicalutamide in Phase 2 CRPC trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:28AM CDT

MDVN: 106.81 (-2.19)

Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 5:12PM CDT
Amgen (AMGN) submits regulatory application for its cholesterol-lowering candidate, Repatha, in Japan.
LCI: 59.93 (+2.37), CBM: 45.61 (+1.91), AMGN: 154.10 (+2.79)

Best One-Drug Wonder Stock for 2015
Brian Orelli, Keith Speights, and George Budwell, The Motley Fool - Motley Fool - Sun Mar 22, 6:01AM CDT
If a biotech wants to become the next drugmaker with multiple blockbusters on the market, it has to start at the bottom with a single drug. We asked our biotech experts for their top picks for companies with just a single drug on the market. Read...
MDVN: 106.81 (-2.19), OREX: 4.70 (+0.04), ISIS: 53.50 (+0.42)

Amgen JV submits regulatory application in Japan for cholesterol med
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:59AM CDT

AMGN: 154.10 (+2.79)

United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:40PM CDT
United Therapeutics' (UTHR) cancer drug Unituxin gained FDA approval plus a priority review voucher for the treatment of pediatric patients suffering from high-risk neuroblastoma.
LCI: 59.93 (+2.37), UTHR: 171.57 (+3.88), SLXP: 172.96 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tragedy Highlights Need for E-bike Safety Overhaul

Updated Category News Views 5

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

Continue Reading
Fast Guard Elevates Nationwide Fire Watch Mission

Updated Category News Views 2

Fast Guard: The Unseen Shield Behind Property Safety Hollywood, Florida might be best known for its sun-kissed beaches, but in the world of fire safety, it’s the nerve center for emergency fire watch response. Fast Guard Service isn’t just any run-of-the-mill security outfit; it’s rapidly becoming the unsung hero of property managers across the nation. When those...

Continue Reading
Why Liver Nurture Taps into Health Sector Trends

Updated Category News Views 5

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Continue Reading
Flying Car Regulatory Sandbox Begins in UAE

Updated Category News Views 7

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Continue Reading
Quay Dominates 2026 Sunglasses Review for Variety

Updated Category News Views 4

Sunglasses Designed for Every Face Type When it comes to picking the right pair of shades, face shape is only part of the equation. Expert Consumers just dropped their 2026 verdict, spotlighting Quay as the go-to brand for those wider faces, tricky nose bridges, and the noggins that run a tad larger than average. Forget what you heard about one-size-fits-all. This...

Continue Reading
Beta Bionics Lawsuit Deadline: Investors Face November 3 Cut-off

Updated Category News Views 5

Looming Deadline for Beta Bionics Investors Time's ticking fast for those holding onto Beta Bionics (BBNX) stock who might've been caught in a web of undisclosed risks and regulatory misses. Investors feeling the pinch from this fiasco have till November 3, 2026, to throw their hat in the ring as lead plaintiffs in the class action lawsuit out of California. The...

Continue Reading
Med Spa Visits: Key Insights from Lindsey Smith

Updated Category News Views 4

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...

Continue Reading
China's Tech Success Echoes in Global Living Rooms

Updated Category News Views 4

A New Player in Global Tech If you've been sleeping on China's tech scene, it's time to wake up. Moonshot AI just launched Kimi K3, the largest open-source model by parameters we've seen, a significant leap in artificial intelligence that's catching even the eyes of folks who hardly touch technology—like retirees in Italy. Rapid AI Advancements China's story isn't about...

Continue Reading
Papa John's Faces Class Action Over Misleading Info

Updated Category News Views 5

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Continue Reading
Hainan Airlines' Dedication Keeps It atop Skytrax

Updated Category News Views 5

Fifteen years of soaring high: now that's something worth taking to the bank—or the air. Hainan Airlines has just bagged the SKYTRAX Five-Star Airline rating once again, handed out at this year's World Airline Awards ceremony. When it comes to delivering quality, they're flying high on the charts, landing among the World's Best Airlines Top 10. And in the wild world of...

Continue Reading

Top 5 Most Recently Viewed Articles

Hospital Da Luz Pioneers Robotic Surgery with Genesis System

Updated Category News Views 149

Advancements in Robotic Surgery at Hospital Da Luz In exciting news from Lisbon, Portugal, Hospital da Luz has made history by becoming the first institution in the country to implement the Genesis Robotic Magnetic Navigation (RMN) System. This system promises to revolutionize how complex heart conditions are diagnosed and treated, further establishing the hospital’s...

Continue Reading
Dayforce Insider Selling: What Investors Should Know

Updated Category News Views 170

Understanding Recent Insider Trading at Dayforce In a notable move within the corporate landscape, a 10% owner of Dayforce (NYSE: DAY), PRICE T ROWE ASSOCIATES INC MD, recently disclosed an insider sale of shares amounting to $307,641. This sale occurred on a recent date, highlighting significant shifts within the company. Details of the Insider Sale On a recent filing...

Continue Reading
Empower Your Kubernetes Workflows with Argo CD Version 3 Update

Updated Category News Views 393

Revolutionizing Kubernetes Management with Argo CD v3 In the dynamic world of cloud-native computing, where efficiency and reliability are paramount, the release of Argo CD v3 marks a significant leap forward. This update comes from the Cloud Native Computing Foundation (CNCF), known for fostering robust ecosystems for innovative software solutions. Argo CD v3 is set to...

Continue Reading
Transforming $1000 into $6980: Insight Enterprises Growth

Updated Category News Views 126

Investment Potential of Insight Enterprises Insight Enterprises (NASDAQ: NSIT) has shown remarkable performance in the stock market over the past 15 years. With an annualized return of 13.85%, this company has outperformed many investments, creating significant value for shareholders. The Growth of a $1000 Investment Imagine if an investor decided to invest $1000 in NSIT...

Continue Reading
Bitcoin vs Gold: Two Futures on America’s Economy

Updated Category News Views 145

Wellington-Altus Chief Market Strategist James Thorne dropped a bombshell: buying Bitcoin (CRYPTO: BTC) is essentially betting on Trump’s economic reforms hitting home runs, whereas grabbing gold is like betting against America winning. This stark dichotomy reveals how traders are parsing the future—one asset thrives if the economic ship rights itself, and the other...

Continue Reading